ZYNLONTA Combo Boosts PFS to 6.1 Months and 39.5% CR Rate
ADC•ZYNLONTA combination therapy in the LOTIS-5 Phase 3 trial extended median progression-free survival to 6.1 months versus 4.7 months with standard immunochemotherapy and boosted complete response rate to 39.5% versus 26.7%. Jefferies set an $84 per share target, implying over 13% upside.
1. Phase 3 Trial Outcomes
The LOTIS-5 Phase 3 trial evaluated ZYNLONTA in combination with another agent for relapsed or refractory DLBCL patients, successfully meeting its primary endpoint by outperforming standard immunochemotherapy in delaying disease progression.
2. Efficacy Metrics
Patients treated with the combination achieved a median progression-free survival of 6.1 months compared to 4.7 months for standard therapy and recorded a 39.5% complete response rate versus 26.7%, indicating a significant efficacy advantage.
3. Safety Profile
The ZYNLONTA arm exhibited a higher incidence of serious adverse events relative to standard treatment, highlighting the need to weigh enhanced efficacy against potential safety risks during regulatory evaluation.
4. Analyst Outlook and Valuation
Jefferies assigned an $84 price target to ADC Therapeutics, reflecting confidence in ZYNLONTA’s commercial prospects and suggesting a 13.28% upside as the company prepares discussions with regulatory authorities.
